Effects of Saxagliptin on Adipose Tissue Inflammation in Humans

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

Also called NCT02285985

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02285985
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02285985. Randomized; double masking; primary purpose treatment. Start 2013-02 (actual); primary completion 2019-10-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Saxagliptin on Adipose Tissue Inflammation in Humans
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
Saxagliptin
Intervention (Drug)
Placebo
Lead sponsor
Phoenix VA Health Care System (class: US federal agency)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct02285985
Content hash
daf727536b2ee5d81216b8b917ac27a5ad0968c8ae78c73424cc3fc0ef8b31bd